CSL Shares Fall to Eight-Year Low After Weak Half-Year Results and Leadership Change
CSL Ltd reported a weaker first-half performance, with underlying net profit falling and reported earnings hit hard by restructuring costs and asset write-downs. The company also announced an interim CEO and expanded its buyback program even as it kept full-year guidance intact. The Sydney-listed biotech saw its stock drop sharply, reaching levels…